Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of oxipurinol in autosomal dominant polycystic kidney disease

Next Previous
Trial Profile

A phase II trial of oxipurinol in autosomal dominant polycystic kidney disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxipurinol (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 13 Aug 2018 According to a XORTX Therapeutics media release, the company with its collaborative partner, Cato Clinical Research, has filed its pre-IND meeting documents with the FDA. The meeting with the FDA has been scheduled for September 20, 2018.
  • 28 Jun 2018 According to a XORTX Therapeutics media release, the company has collaboration with The Polycystic Kidney Disease Foundation fo this trial.
  • 08 Jun 2018 According to a XORTX Therapeutics media release, has filed its pre-IND meeting request letter with the FDA.The meeting with the FDA has been scheduled for September 10, 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top